| payload |
{"created_at":"2026-04-10T03:04:31.796 {"created_at":"2026-04-10T03:04:31.796915+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:847b761356685ea8","evidence_event_ids":["evt_51246816e27b"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001412071-26-000004.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001412071-26-000004.txt","company":"Vistagen Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001412071-26-000004.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_f503e3eec4635015","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001412071-26-000004.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:16:33.393602+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001412071-26-000004.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1411685/0001412071-26-000004.txt","source_event_id":"evt_51246816e27b","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"64a4a1ab757d8645","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-09","2026-04-07","2026-04-07 (Grant Date reference)","2036-04-07 (as shown in filing values)","2019 Omnibus Equity Incentive Plan (as referenced)","2011-06-10 (name change reference)","2007-09-06 (name change reference)"],"entities":[{"asset_class":"equity","name":"Vistagen Therapeutics, Inc.","relevance":"high","symbol":"VTGN","type":"issuer"},{"asset_class":"equity","name":"Shawn Singh","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"other","name":"Nick B. Tressler","relevance":"low","symbol":"","type":"attorney_in_fact"},{"asset_class":"other","name":"Reid G. Adler","relevance":"low","symbol":"","type":"attorney_in_fact"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; only the current Form 4 contents are shown.","The filing text excerpt does not explicitly state whether these options were newly granted in this filing relative to any prior disclosure (no prior-state comparison data included).","No transaction \u201cacquired/disposed\u201d totals beyond the option quantities and exercise price are shown in the provided excerpt.","The excerpt includes \u201c2036-04-07\u201d in the filing values, but the meaning (e.g., expiration/term) is not explicitly explained in the provided text."],"key_facts":["SEC filing: Form 4 (conformed submission type: 4) for Vistagen Therapeutics, Inc.","Filed as of date: 2026-04-09; conform ed period of report: 2026-04-07.","Reporting owner: Shawn Singh; position shown as \u201cPresident and CEO\u201d.","Two option grants are disclosed: (1) Incentive Stock Option (right to buy) with exercise price 0.5358 and option quantity 3,732; (2) Non-Qualified Stock Option (right to buy) with exercise price 0.5358 and option quantity 71,268.","The options \u201crepresent stock options (the 'Options') granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.\u201d","Vesting terms disclosed: \u201c25% of the Options will vest on the six-month anniversary of April 7, 2026 \u2026 and \u2026 25% installments every six months thereafter until \u2026 fully vested on the two (2) year anniversary of the Grant Date.\u201d","Supporting document included: \u201cPower of Attorney\u201d (EX-24) authorizing named attorneys-in-fact to submit and file SEC forms including Forms 3, 4 and 5."],"numeric_claims":[{"label":"Incentive Stock Option quantity","value":"3732"},{"label":"Non-Qualified Stock Option quantity","value":"71268"},{"label":"Exercise price (both option types)","value":"0.5358"},{"label":"Grant date","value":"2026-04-07"},{"label":"Vesting start reference","value":"six-month anniversary of April 7, 2026"},{"label":"Full vesting reference","value":"two-year anniversary of the Grant Date"}],"primary_claim":"On 2026-04-09, Vistagen Therapeutics, Inc. filed Form 4 reporting that Shawn Singh received stock options granted on 2026-04-07 with vesting starting at the six-month anniversary of April 7, 2026 and completing at the two-year anniversary.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Vistagen Therapeutics, Inc. (VTGN) filed a Form 4 on 2026-04-09 covering transactions reported for the period ending 2026-04-07 by reporting owner Shawn Singh. The filing discloses stock option grants (incentive stock options and non-qualified stock options) with a specified vesting schedule.","topics":["SEC Form 4","insider transactions","stock option grants","vesting schedule","EDGAR power of attorney"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 Vistagen Therapeutics, Inc. \u00b7 Filed 20260409","ticker":"VTGN","tickers":["VTGN"],"title":"VTGN filed 4","url":"https://www.sec.gov/Archives/edgar/data/1411685/0001412071-26-000004.txt"}}... |